GSK

GlaxoSmithKline limits Shingrix orders, delays TV commercials amid 'unprecedented' demand
GlaxoSmithKline limits Shingrix orders, delays TV commercials amid 'unprecedented' demand
Fierce Pharma
GSK
Shingrix
shingles
vaccines
Flag link:
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Yahoo/Reuters
GSK
Gilead Sciences
HIV
AIDS
Dolutegravir
lamivudine
Biktarvy
Flag link:
5 Experimental New Drugs That Could Be Worth $47 Billion
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
GSK2857916
GSK
brolucizumab
Novartis
aducanumab
Biogen
upadacatinib
AbbVie
VX-659 + tezacaftor + ivacaftor
Vertex Pharmaceuticals
Flag link:
Treehouse to roller rink: A look at Parmer RTP's $80M overhaul of former GSK campus (Photos)
Treehouse to roller rink: A look at Parmer RTP's $80M overhaul of former GSK campus (Photos)
Bizjournals.com
GSK
RTP
real estate
Flag link:
GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL
GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL
Endpoints
Mylan
FDA
Advair
GSK
complete response letter
Flag link:
ViiV Healthcare reports positive results for late-stage HIV trials
ViiV Healthcare reports positive results for late-stage HIV trials
Marketwatch
ViiV Healthcare
GSK
Pfizer
Shionogi
HIV
clinical trials
Dolutegravir
lamivudine
Flag link:
GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report
GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report
Fierce Pharma
GSK
Merck
Sanofi
Pfizer
Novavax
vaccines
Flag link:
GSK’s high-level management makeover continues as CEO Emma Walmsley oversees changing of the guard
GSK’s high-level management makeover continues as CEO Emma Walmsley oversees changing of the guard
Endpoints
GSK
Emma Walmsley
Flag link:
GlaxoSmithKline boosted Shingrix educational efforts after seeing administration, storage errors in launch
GlaxoSmithKline boosted Shingrix educational efforts after seeing administration, storage errors in launch
Fierce Pharma
drug launches
GSK
Shingrix
shingles
vaccines
Flag link:
EATRIS Announces Novel Public-Private Collaboration for Imaging Method Development in Inflammatory Diseases
EATRIS Announces Novel Public-Private Collaboration for Imaging Method Development in Inflammatory Diseases
CP Wire
GSK
EATRIS
imaging
inflammatory diseases
PET
MRI
Flag link:
EATRIS Announces Novel Public-Private Collaboration for Imaging Method Development in Inflammatory Diseases
GSK
EATRIS
imaging
inflammatory diseases
PET
MRI
Flag link:
China Focused Brii Biosciences Launches With $260 Million and Team of Industry Veterans
China Focused Brii Biosciences Launches With $260 Million and Team of Industry Veterans
CP Wire
Brii Biosciences
China
GSK
Flag link:
GSK’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old
GSK’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old
Drug Delivery Business News
GSK
FDA
Arnuity Ellipta
asthma
pediatric
Flag link:
GlaxoSmithKline touts long-term study of biologic treatment for severe eosinophilic asthma
GlaxoSmithKline touts long-term study of biologic treatment for severe eosinophilic asthma
Drug Delivery Business News
GSK
eosinophilic asthma
mepolizumab
Flag link:
Regulators flag possible birth defect link to GSK's HIV drug
Regulators flag possible birth defect link to GSK's HIV drug
Yahoo/Reuters
GSK
HIV
Dolutegravir
birth defects
EMA
FDA
Flag link:
Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die
Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die
Yahoo/Bloomberg
GSK
Advair
asthma
generics
Flag link:
GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M
GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M
Fierce Pharma
GSK
vaccines
earnings
Shingrix
shingles
Flag link:
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
Fierce Pharma
GSK
HIV
Biktarvy
Gilead Sciences
Triumeq
Tivicay
Flag link:
Look at our new launches, GSK urges, as its respiratory woes steal the limelight
Look at our new launches, GSK urges, as its respiratory woes steal the limelight
Fierce Pharma
GSK
earnings
HIV
Shingrix
Flag link:
GSK boss rethinking R&D incentives, as Barron and Sin seek out early and late-stage ops
GSK boss rethinking R&D incentives, as Barron and Sin seek out early and late-stage ops
Fierce Biotech
GSK
R&D
Emma Walmsley
Flag link:

Pages